Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for TDS Pharm Co., Ltd. (464280:KRX), powered by AI.
TDS Pharm Co., Ltd. is currently trading at ₩6,910. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for TDS Pharm Co., Ltd. on Alpha Lenz.
TDS Pharm Co., Ltd.'s P/E ratio is 8.4.
“TDS Pharm Co., Ltd. trades at a P/E of 8.4 (undervalued) with solid ROE of 10.5%.”
Ask for details →TDS Pharm Co., Ltd. is a prominent player in the pharmaceutical industry, specializing in the research, development, manufacture, and sale of pharmaceutical products. The company plays a critical role in advancing health care by providing essential medications and innovative therapeutic solutions. TDS Pharm focuses on various therapeutic areas including but not limited to oncology, cardiology, and neurology, which are pivotal sectors given the rising demand for specialized health care solutions. The organization's primary function is to deliver high-quality pharmaceuticals that adhere to regulatory standards, ensuring the safety and efficacy of its product offerings. By investing heavily in research and development, TDS Pharm seeks to drive innovation and bring new drugs to the market that can address unmet medical needs. In the financial market, TDS Pharm Co., Ltd. is seen as an influential entity within the pharmaceutical sector, contributing to the overall market health through its robust product pipeline and strategic partnerships. This helps to not only meet global health challenges but also sustain its growth and presence as a key player in the industry.
“TDS Pharm Co., Ltd. trades at a P/E of 8.4 (undervalued) with solid ROE of 10.5%.”
Ask for details →TDS Pharm Co., Ltd. (ticker: 464280) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - General). Market cap is $35.9B.
The current price is ₩6,910 with a P/E ratio of 8.41x and P/B of 0.84x.
ROE is 10.52% and operating margin is 13.63%. Annual revenue is $27.6B.